Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026PRNewsWire · 4 days ago
Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary EndpointBenzinga · Oct 15, 2026
Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development ProgramGuruFocus · Oct 14, 2026
Vanda says anxiety drug failed main goal of late-stage study, puts program on holdReuters · Oct 14, 2026
Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development ProgramPRNewsWire · Oct 14, 2026
Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Rating Reaffirmed as “Buy” by HC WainwrightDefense World · Oct 5, 2026Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$0.58 | -$1.04 | Miss |
| May 6, 2026 | -$0.53 | -$0.82 | Miss |
| Feb 11, 2026 | -$2.18 | -$2.39 | Miss |
| Oct 29, 2025 | -$0.31 | -$0.38 | Miss |
| Jul 31, 2025 | -$0.34 | -$0.46 | Miss |
| May 7, 2025 | -$0.55 | -$0.50 | Beat |